Methods of oocysts collection and disinfection for manufacturing a live coccidiosis vaccine

A cost-effective coccidiosis vaccine is produced through efficient oocyst washing and disinfection, addressing high production costs and contamination issues in existing vaccines, ensuring effective immunization.

KR103046617B1Active Publication Date: 2026-11-10IND COOP FOUND CHONBUK NAT UNIV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
KR1020230042096
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-03-30
Publication Date
2026-11-10
Estimated Expiration
2043-03-30

AI Technical Summary

Technical Problem

Existing coccidiosis vaccines face high production costs due to the need for specific-pathogen-free (SPF) environments and inefficient oocyst washing methods, leading to resource-intensive processes and potential loss of oocysts.

Method used

A method involving washing oocysts with saturated sugar and salt solutions, followed by disinfection with sodium hypochlorite, citric acid, sulfuric acid, and sodium hydroxide, reduces the need for SPF environments and minimizes contamination by E. coli and aerobic bacteria.

Benefits of technology

The method produces a cost-effective coccidiosis vaccine with enhanced vaccination efficacy by maintaining sporozoite viability and reducing secondary infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023036110077-PAT00004_ABST
    Figure 112023036110077-PAT00004_ABST
Patent Text Reader

Abstract

The present invention relates to a method for manufacturing a coccidium vaccine, and in particular, it has been confirmed that the coccidium vaccine produced by the above method reduces the number of colonies of Escherichia coli and aerobic bacteria. In addition, the live vaccine produced by the above method has excellent vaccination efficacy and can be usefully applied in related fields.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The objective of the present invention is to provide a method for collecting, a disinfection method, and a method for manufacturing a vaccine for coccidiosis. Background Technology

[0002] Coccidiosis is a parasitic disease caused by protozoa of the genus Eimeria, belonging to the class Spore-protozoa, which primarily affects livestock such as cattle and pigs, as well as poultry including chickens. Coccidiosis is one of the major livestock diseases in the livestock industry, with an estimated annual loss of over $500 million worldwide.

[0003] Coccidiosis occurs in livestock that have ingested coccidium oocysts. Coccidium oocysts are known to have high resistance to the external environment, and their wall consists of two layers: an inner and an outer layer. The outer layer of the wall is a gelatinous substance that strongly resists physical external pressure, while the inner layer is rich in nucleoproteins and strongly resists chemical stimuli, namely disinfectants. Coccidium oocysts possessing these characteristics are generally known to retain infectivity in the natural environment.

[0004] Meanwhile, when livestock are infected with coccidiosis, active treatment is carried out when diarrhea or a decline in growth becomes evident; however, in farms with low levels of contamination, symptoms are mild, making it difficult to recognize the presence of coccidiosis. Nevertheless, it is so widespread that it is reasonable to assume that most livestock on farms are infected.

[0005] Therefore, when some livestock and poultry are infected with coccidia, Eimeria oocysts invade the intestinal mucosal cells (villi) within the host animal's intestine, impairing their function and delaying their growth, and destroying the intestinal mucosal cells, thereby causing injury. As a result, there is a problem of secondary infection occurring in the host animal due to bacteria such as E. coli.

[0006] Coccidiosis vaccines are divided into live vaccines and egg-based vaccines.

[0007] The manufacturing process of existing coccidium vaccines is carried out in a specific-pathogen-free (SPF) environment to prevent the spread of other diseases. While the SPF environment is critical to the vaccine manufacturing process, it is a cause of high production costs. In addition, coccidium vaccines use Eymeria eggs ( Eimeria By collecting oocysts and artificially infecting a small number of protozoa, only the oocysts found in chicken feces are collected and used as a vaccine.

[0008] Nangye University vaccine is Emeria eggs ( Eimeria This method involves producing coccidiosis vaccines by infecting incubating fertilized eggs after primary and secondary decystization of oocysts, and it is also a method capable of achieving attenuation. However, multiple passages are required to acclimate the coccidiosis to the eggs, and this process is time-consuming. Once acclimated, the protozoa can be continuously used as an egg-pass vaccine, but the production cost is higher than that of live vaccines because it requires more resources.

[0009] Existing Aimeria eggs ( Eimeria The washing method for oocysts is based on specific gravity or size, and Eymeria eggs ( Eimeria Methods utilizing the specific gravity of oocysts include 1) a method using sugar and salt solutions available in general foods, and 2) a method using chemical substances (Percoll, etc.), and Eymeria eggs ( Eimeria There was a separation method using a column that utilized the size characteristics of oocysts.

[0010] Conventional fecal washing methods for obtaining Eymeria protozoa required continuously adjusting sugar solutions (preparing solutions of various concentrations) and centrifuge conditions. This method [causes] Eymeria eggs during the washing process ( Eimeria There was discomfort due to the loss and progression of oocysts.

[0011] Accordingly, the inventors of the present invention, using the above method of making vaccines, Aimeria ( Eimeria A method was devised to wash and disinfect the feces of chickens infected with a protozoan called ) to minimize SPF environmental requirements and significantly lower the price of the vaccine, thereby inventing a coccidiosis vaccine that can be used in general broiler chickens. The problem to be solved

[0012] The objective of the present invention is (a) Aimeria eggs ( Eimeria Step of washing oocysts;

[0013] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; the present invention provides a method for manufacturing a coccidiosis vaccine comprising: (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant.

[0014] In addition, the objective of the present invention is (a) Aimeria eggs ( Eimeria Step of washing oocysts;

[0015] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; the present invention provides a coccidiosis vaccine manufactured by a method for manufacturing a coccidiosis vaccine comprising: (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant. means of solving the problem

[0016] The present invention relates to (a) Eymeria eggs ( Eimeria Step of washing oocysts;

[0017] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; a method for manufacturing a coccidiosis vaccine is provided.

[0018] In addition, the present invention (a) Aimeria eggs ( Eimeria Step of washing oocysts;

[0019] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; the present invention provides a coccidium vaccine manufactured by a method for manufacturing a coccidium vaccine comprising: (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant. Effects of the invention

[0020] The present invention relates to a method for manufacturing a coccidium vaccine, and in particular, it has been confirmed that the coccidium vaccine produced by the above method reduces the number of colonies of Escherichia coli and aerobic bacteria. In addition, the live vaccine produced by the above method has excellent vaccination efficacy and can be usefully applied in related fields. Brief explanation of the drawing

[0021] FIG. 1 shows the survival rate of Eimeria sporosome (after washing the novel coccidium vaccine of the present invention and disinfecting with sodium hypochlorite, citric acid, sulfuric acid, and sodium hydroxide) Eimeria sporozoite viability) This is the diagram shown. (NaClO, Sodium hypochlorite, 9%; C6H8O7, Citric acid, 70%; H2SO4, Sulfuric acid, 98%; NaOH, Sodium hydroxide, 70%. Values ​​are presented as the mean ± SE. a-d Different letters represent significant differences.) Figure 2 is a figure showing the number of oocysts released according to the time period after vaccination with the coccidiosis vaccine produced according to the present invention, based on the number of oocysts. Figure 3 is a figure showing the number of oocysts released by secondary infection mimicking natural infection of the same individual in Figure 2. FIG. 4 is a diagram briefly illustrating a method for collecting oocysts for manufacturing a new live coccidiosis vaccine of the present invention. Specific details for implementing the invention

[0022] Hereinafter, the present invention will be described in detail with reference to the attached drawings for embodiments of the present invention. However, the following embodiments are presented as examples of the present invention, and if it is determined that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the essence of the present invention, such detailed description may be omitted, and the present invention is not limited by this. The present invention is capable of various modifications and applications within the scope of the claims set forth below and the equivalent scope interpreted therefrom.

[0023] Furthermore, the terminology used in this specification is used to appropriately describe preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs. Accordingly, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, unless specifically stated otherwise, this means that it does not exclude other components but may include additional components.

[0024] All technical terms used in this invention, unless otherwise defined, are used in the sense generally understood by those skilled in the art in the relevant field of this invention. Furthermore, while preferred methods or feeds are described herein, similar or equivalents are also included within the scope of this invention. The contents of all publications cited as references in this specification are incorporated into this invention.

[0025] In one embodiment, the present invention comprises (a) an Aimeria egg ( Eimeria Step of washing oocysts;

[0026] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; a method for manufacturing a coccidiosis vaccine is provided.

[0027] In one embodiment, the Aimeria egg of step (a) ( Eimeria Washing with sugar or salt at a ratio of 3 times the volume of the oocysts, but not limited to this.

[0028] In one embodiment, the sugar or salt is included in a volume ratio of 3:1 relative to Eimeria oocysts, but is not limited thereto.

[0029] In one embodiment, the disinfectant is sodium hypochlorite, citric acid, sulfuric acid, and sodium hydroxide, but is not limited thereto.

[0030] In one embodiment, the disinfectant is treated at a concentration of 1 to 100% for 1 to 15 minutes, but is not limited thereto.

[0031] In one embodiment, the centrifugation conditions of the method are standardized to 2,000 to 4,000 RPM and 5 to 15 min, but are not limited thereto.

[0032] In one embodiment, the coccidiosis vaccine produced by the above method reduces the number of colonies of E. coli and aerobic bacteria, but is not limited thereto.

[0033] In one embodiment, the coccidium vaccine is a live vaccine or an egg-based vaccine, but is not limited thereto.

[0034] In one embodiment, the present invention comprises (a) an Aimeria egg ( Eimeria Step of washing oocysts;

[0035] (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; thereby providing a coccidium vaccine prepared with a coccidium vaccine.

[0037] Vaccines are intended to provide a defense mechanism through the body's immune system by administering bacteria or viruses that have been weakened or detoxified, or their extracts, into the body. For example, BCG is designed to provide immune defense against tuberculosis bacteria; the bacteria are serially cultured in cattle to lose their pathogenicity. Since the bacteria or viruses inoculated as vaccines do not possess pathogenicity, they can provide immunity without causing infection, and vaccines that use attenuated pathogens are called live vaccines.

[0038] Live vaccines use bacterial or viral variant strains whose pathogenicity has been weakened through methods such as subculture in a live state. They are used when sufficient immunity cannot be obtained with inactivated vaccines.

[0039] Inactivated vaccines, also known as killed vaccines, were developed because the use of live vaccines can actually cause disease in immunocompromised individuals. These vaccines are produced by culturing pathogens and then inactivating them through heat, chemicals, or cell fractionation methods; while they can be safely used even by immunocompromised patients, they require multiple doses due to a weak immune response. However, this stepwise approach also has the advantage of allowing the immune response to be applied sequentially from low to high levels.

[0040] However, in the case of coccidiosis, there are differences compared to general bacteria or viruses. Unlike vaccines for other diseases, the coccidiosis vaccine involves infecting a small number of coccidiosis protozoa (within a range where pathogenicity does not appear). Although many passages are required to obtain the protozoa by infecting incubating fertilized eggs (after artificially decystizing) to achieve attenuation, they do not exhibit pathogenicity because they are attenuated. Furthermore, inactivated vaccines are not applicable to coccidiosis.

[0041] The present invention will be explained in more detail through the following examples. However, the following examples are merely illustrative of the content and scope of the technical concept of the present invention and do not limit or alter the technical scope of the present invention. Furthermore, it can be easily determined by those skilled in the art that various modifications and changes are possible within the scope of the technical concept of the present invention based on these examples.

[0043] Example 1. Washing method when producing the coccidiosis live vaccine or egg-borne vaccine of the present invention

[0044] In the production of the live coccidium vaccine of the present invention, the washing method used in the production of conventional coccidium vaccines used sugar solutions of various concentrations, but the washing method of the present invention used a saturated sugar solution and a saturated salt solution, and the centrifuge conditions were standardized to 3,000 RPM and 10 min.

[0045] Accordingly, the method for collecting oocysts for the production of the coccidium vaccine of the present invention is briefly shown in FIG. 4.

[0046] The specific washing method is ① 0.1 cm after diluting the feces of chickens infected with coccidiosis 2① Filtration and centrifugation were performed using a mesh filter. ② Saturated sugar solution was added to the pellet obtained from centrifugation in a volume at least three times that of the pellet, homogenized, and centrifuged. ③ The supernatant obtained from centrifugation was collected, diluted with distilled water (DW) in a volume 10 times that of the supernatant, homogenized, and centrifuged. ④ Saturated salt solution was added to the pellet obtained from centrifugation in a volume at least three times that of the pellet, homogenized, and centrifuged. ⑤ Only the supernatant was collected after centrifugation, diluted with DW in a volume 10 times that of the supernatant, homogenized, and centrifuged. ⑥ The pellet obtained from centrifugation was resuspended in a 2.5% potassium dichromate solution and subjected to differentiation (27 ± 2℃, 80% RH). ⑦ It was stored at 4℃ until analysis.

[0048] Example 2. Disinfection method when producing the coccidiosis live vaccine or egg-borne vaccine of the present invention

[0049] In the production of the coccidiosis vaccine of the present invention, since many processes are not carried out in an SPF environment, a disinfection process is essential. The method involves, first, ① the Eymeria eggs washed in Example 1 above ( Eimeria1 ml of the oocysts sample was dispensed into 50 ml conical tubes, and ② centrifuged (3,000 rpm, 10 min). After discarding the supernatant, 2 ml of each chemical disinfectant was added, and the tubes were transferred to ice shaking incubation. The chemical disinfectants used were sodium hypochlorite (7585-1405, DAEJUNG, KOREA), citric acid (2561-4405, DAEJUNG, KOREA), sulfuric acid (7683-4100, DAEJUNG, KOREA), and sodium hydroxide (7571-4400, DAEJUNG, KOREA). ③ After removing the above chemical disinfectant, add 10 ml of DW, vortex, centrifuge (3,000 rpm, 10 minutes), and discard the supernatant, repeating this process at least 3 times.

[0050] As a result, disinfected Emeria eggs in a pellet ( Eimeria oocysts) remained, and the number of E. coli and total aerobic bacteria in the coccidiosis vaccine before disinfection is shown in Table 1, and the number of colonies of E. coli in the coccidiosis vaccine after disinfection by the washing and disinfection method of the present invention is shown in Table 2, and the number of colonies of aerobic bacteria is shown in Table 3.

[0051] (unit: CFU / ml) Microbial coliform bacteria Total aerobic bacteria Washed Eimeria oocysts 91,100,000 185,300,000

[0052] (unit: CFU / ml) coliform bacteria 1% 5% 10% (9%) 20% 50% 98% (70%) Sodium hypochlorite 1 min 1.0 0.6 0.3   2 min 0.7 0.3 0.1 5 min 0.4 0.1 0.0 10 min 0.2 0.0 0.1 Citric acid 1 min 732222.2 66888.9 5474.4 132.9 0.6 0.3  2 min 684444.4 77666.7 2357.8 149.7 0.1 0.0 5 min 661111.1 27222.2 183.3 39.1 0.4 0.1 10 min 612222.2 14777.8 24.4 49.9 0.3 0.0 Sulfuric acid 1 min 20.7 1.0 0.0 0.0 0.0 0.0 2 min 20.2 0.8 0.0 0.0 0.0 0.0 5 min 11.7 0.4 0.0 0.0 0.0 0.0 10 min 8.7 0.4 0.0 0.0 0.0 0.0 Sodium hydroxide 1 min 26.0 0.3 0.0 12.6 0.0 0.1 2 min 14.6 0.1 0.0 0.0 0.0 0.0 5 min 10.2 0.0 0.1 0.0 0.0 0.0 10 min 5.2 0.1 0.0 0.1 0.0 0.0

[0053] (unit: CFU / ml) Total aerobic bacteria 1% 5% 10%(9%) 20% 50% 98%(70%) Sodium hypochlorite 1 min 3.2 0.2 0.5   2 min 0.7 0.0 0.0 5 min 0.0 0.0 0.2 10 min 0.0 0.0 0.1 Citric acid 1 min 1055555.6 197666.7 26677.8 81.1 67.8 44.4  2 min 904444.4 230111.1 16956.7 174.4 55.6 23.7 5 min 1008888.9 97666.7 1884.4 37.8 18.9 9.3 10 min 933333.3 56777.8 165.6 24.4 17.8 8.8 Sulfuric acid 1 min 895.6 386.1 366.7 231.3 12.6 0.0 2 min 997.8 364.4 394.4 241.3 6.2 0.0 5 min 827.8 254.4 318.9 177.2 2.0 0.0 10 min 915.6 265.6 331.1 148.6 1.3 0.0 Sodium hydroxide 1 min 793.3 490.0 224.4 86.7 12.2 2.2 2 min 740.0 531.1 197.8 96.7 18.9 3.7 5 min 758.9 444.4 156.7 43.3 11.1 1.8 10 min 600.0 315.6 101.1 23.3 11.1 1.7

[0054] The maximum concentration of sodium hypochlorite in Tables 2 and 3 is 9%, and the maximum concentration of citric acid and sodium hydroxide was set to 70% because they do not dissolve in the solvent at high concentrations.

[0055] As a result, it was confirmed that as the concentration of each disinfectant increased, the inhibitory effect against E. coli or total aerobic bacteria was superior.

[0057] Example 3. Survival rate of Eymeria sporosome after washing and disinfection according to the present invention ( Eimeria sporozoite viability)

[0058] Viability of Eymeria sporosome after washing and disinfection of the present invention ( Eimeria To verify sporozoite viability, the survival rate of Eymeria sporozoites after disinfection at the maximum concentration of each disinfectant ( Eimeria Sporozoite viability was compared.

[0059] As shown in Fig. 1, the survival rate of Aimeria sporosome ( Eimeria Regarding sporozoite viability, it was confirmed that sulfuric acid and sodium hypochlorite had the best viability among the four disinfectants. This means that disinfectants at effective concentrations do not significantly affect the survival of Eimeria sporozoites, suggesting that when treated with the vaccine, it can prevent the spread of disease caused by other pathogenic microorganisms and maintain its effectiveness as a vaccine.

[0060] However, sodium hypochlorite is less effective for decontamination for cell culture progress, so sulfuric acid is used for Eymeria eggs ( Eimeria It was identified as a chemical disinfectant suitable for disinfecting oocysts.

[0062] Example 4. Inoculation effect of the live coccidiosis vaccine produced by the washing and disinfection method of the present invention

[0063] To confirm the inoculation effect of the coccidiosis vaccine produced by the washing and disinfection method of the present invention, the Eimeria vaccine produced by the present invention is 10 per animal 3 , 10 4 , 10 5 The dogs were each vaccinated at 14 days of age, and thereafter, after a 7-day recovery period, secondary infection (common Eimeria oocysts 10 in the attacking owner) was reported to the same individuals 4(G) and checked the results.

[0064] In the case of the existing Eimeria vaccine, it was confirmed that it tended to amplify within the body, similar to general oocyst infections (Fig. 2). In addition, it was observed that the vaccine was effective as the number of oocysts released during secondary infections was significantly reduced after vaccination (Fig. 3).

[0065] In the previous results, 10 Eimeria oocysts 5 Dog infection generally results in a 50% mortality rate for chickens, and 10 4 Infection in dogs has a significant impact on chickens, but it does not lead to mortality. In the field, there are no cases where a large number of Eimeria oocysts infect at once as in this experiment; it is common for a small number of Eimeria oocysts to infect daily. The experiment confirmed the effectiveness of the vaccine through an extreme case.

[0067] Example 5. Comparison of the conventional egg-path (attenuated) vaccine manufacturing process and the egg-path manufacturing process of the present invention

[0068] To compare the conventional egg-based (attenuated) vaccine manufacturing process and the egg-based manufacturing process of the present invention, first, as shown in Table 4, the conventional live vaccine manufacturing method and the improved method were briefly presented, and as shown in Table 5, the conventional egg-based (attenuated) vaccine manufacturing process and the egg-based manufacturing process of the present invention were presented.

[0069] In the improved method category of Table 5 below, the washing method of the present invention was used in 4. Washing method after breaking fertilized eggs during hatching, and the disinfection method of the present invention was used in 5. Protozoa disinfection.

[0070] Therefore, unlike the live vaccine manufacturing method in Table 4, the egg-pass vaccine in Table 5 is a method of producing attenuated protozoa by decystizing the protozoa and infecting incubating fertilized eggs. It requires at least 50 passages to adapt to eggs, and the entire process of the conventional method had to be SPF-free. As with the conventional method, at least 50 passages were required to adapt to eggs. On the other hand, the manufacturing method of the present invention uses ordinary eggs and shortens the SPF-free process, thereby reducing production costs.

[0072] Existing method Method for manufacturing a live vaccine of the present invention 1. Chicken rearing (feeding SPF feed) 2. Coccidiosis infection 3. Feeding of special feed (digestibility over 90%) 4. Fecal collection 5. Fecal washing 6. Live vaccine preparation 1. Chicken rearing (feeding standard feed) 2. Coccidiosis infection 3. Feeding standard feed 4. Feces collection 5. Feces washing 6. Feces disinfection 7. Live vaccine preparation

[0073] Existing method Method for manufacturing a live vaccine of the present invention 1. Primary and secondary decystization 2. Incubation of SPF fertilized eggs 3. Infection of the erosal membrane of fertilized eggs during incubation 4. Washing after breaking fertilized eggs during incubation 5. Preparation of vaccine for egg lineage 1. Primary and secondary decystization 2. Incubation of standard fertilized eggs 3. Infection of the erosional membrane of fertilized eggs during incubation 4. Washing after breaking fertilized eggs during incubation 5. Disinfection against protozoa 6. Preparation of egg-borne vaccine

[0074] Table 4 above shows the application of the present invention to the manufacturing process of the new live coccidiosis vaccine of the present invention, and the existing method is carried out in an SPF environment, and steps 6 and 7 of the live vaccine manufacturing method of the present invention are carried out in an SPF environment.

[0075] Table 5 above shows the application of the present invention to the manufacturing process of the new coccidiosis egg-borne vaccine of the present invention. The existing method is carried out in an SPF environment, and steps 4, 5, and 6 of the live vaccine manufacturing method of the present invention are carried out in an SPF environment.

[0076] In addition, the existing methods in Tables 4 and 5 require the production of live vaccines by feeding special feed, which places a higher economic burden.

[0078] Embodiments of the present invention have been described above. Those skilled in the art may understand that the present invention may be embodied in modified forms without departing from the essential characteristics of the invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the claims, not by the foregoing description, and all variations within the scope of equivalents should be interpreted as being included in the present invention.

Claims

Claim 1 A method for manufacturing a coccidium vaccine comprising: (a) a step of washing Eimeria oocysts; and (b) a step of disinfecting the washed Eimeria oocysts of (a) with a disinfectant; wherein the washing in step (a) comprises washing with a sugar solution at a volume of 3 times the volume of fecal residue containing Eimeria oocysts; and washing with a salt solution at a volume of 3 times the volume of fecal residue containing Eimeria oocysts; and wherein the disinfectant in step (b) is sulfuric acid, and the sulfuric acid is applied at a concentration of 10 to 98% for 1 to 10 minutes. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 A method according to claim 1, wherein the washing step (a) comprises washing with a sugar solution three times the volume of the fecal residue containing Eimeria oocysts and then centrifuging; and washing with a salt solution three times the volume of the fecal residue containing Eimeria oocysts and then centrifuging; wherein the centrifugation condition is standardized to 5 to 15 min. Claim 7 In claim 1, the coccidiosis vaccine produced by the above method reduces the number of colonies of E. coli and aerobic bacteria. Claim 8 A method according to claim 1, wherein the coccidiosis vaccine is a live vaccine or an egg-based vaccine. Claim 9 Coccidiosis vaccine manufactured by the manufacturing method of claim 1.

Citation Information

Patent Citations

  • Improved method for producing oocysts

    JP2005520492A

  • Coccidial vaccine and method of making and using same

    JP2008538364A

  • Antibiotic-free compositions for the prevention or control of coccidiosis

    JP2020506963A

  • Coccidial vaccine and methods of making and using same

    KR1020070122551A

  • Composition comprising 1-[2-(4-nitro-phenyl)-benz-oxsazol-5-yl]-propan-1-one(1124JH0013) for preventing and treating the disease caused by toxoplasmosis and coccidium

    KR1020110121143A